Paroxetine serum concentrations in depressed patients and response to treatment

scientific article published in May 2005

Paroxetine serum concentrations in depressed patients and response to treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1055/S-2005-864121
P8608Fatcat IDrelease_okb3o2jgyzeazmhzqracdwpcuu
P698PubMed publication ID15902581

P2093author name stringHärtter S
Hiemke C
Gilles M
Heuser I
Deuschle M
Krumm B
Shams M
Kellner S
P433issue3
P304page(s)118-121
P577publication date2005-05-01
P1433published inPharmacopsychiatryQ15757383
P1476titleParoxetine serum concentrations in depressed patients and response to treatment
P478volume38

Reverse relations

cites work (P2860)
Q48858316Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder
Q46052044Benefit of slow titration of paroxetine to treat depression in the elderly
Q40946755Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems
Q36079358Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics
Q46101361Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder
Q43415647Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders
Q48241646Outcome of treatment with antidepressants in patients with hypertension and undetected depression.
Q37791156Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry
Q39313611Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
Q45928085Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
Q36511678Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies
Q36491587Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients
Q33654737The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder

Search more.